Business Wire

PPG Experts to Showcase Future of Automotive Color Styling, Application Technology at Surcar Europe 2021

1.7.2021 16:02:00 EEST | Business Wire | Press release

Share

PPG (NYSE: PPG) today announced that its experts will share the future of sustainable automotive color styling and application technology in presentations at the Surcar Europe 2021 automotive engineering and design show, which is being held this week in Cannes, France.

Sabine Griesbeck, PPG digital transformation technical manager, will discuss the future of color development using digital color styling. A presentation by Sven Reil, PPG automotive application manager, Europe, Middle East and Africa, will cover paint as an enabler for precision application. Both presentations will be given on July 1.

PPG’s digital styling program will enable automotive designers to execute exceptionally realistic three-dimensional modeling of automotive colors and effects on virtual car designs and surfaces, significantly speeding up the process of developing new colors and reducing waste.

“Prior to the development of PPG's digital color styling program, the time taken from the designer’s vision to a final color could be as long as nine months,” said Griesbeck. “The color team developed several different variations of a color. These are then applied to test panels that are sent to the customer for review. This generated waste, and having small panels does not give a good real-world representation of the color.”

PPG’s digital styling library features a proprietary “speed shape” that accurately depicts the interaction of color, geometry and light. It also offers the option to download digital color files that are fully compatible with industry-standard color-rendering software. This enables design teams to collaborate with PPG experts directly, remotely and in real time.

“This is the first step in fully digitizing the entire color styling process for PPG customers,” Griesbeck said. “Imagine if in the future you can adjust a color virtually according to your wishes, and the new color design is digitally born and ready to use in production. There are also significant sustainability benefits, as we expect this new way of working will reduce the carbon dioxide (CO2) footprint through lower material and energy consumption.”

Individualization and customization are also leading to an increased demand for two-tone schemes. PPG’s breakthrough precision application technology for automotive coatings significantly streamlines the painting of these schemes, producing crisp paint edges without the use of masking and other time-intensive steps currently required to achieve a two-tone finish.

“The conventional process requires that a vehicle be fully painted before paint shop personnel mask off areas that will not receive the second color,” said Reil. “The vehicle must then be run through the paint line or a repair line a second time to apply the contrasting color. In addition to reducing paint shop capacity, this second run can add significant material, labor and energy costs to the total unit cost of the vehicle.”

The precision process uses a specially designed PPG coating as well as innovative application heads that apply the paint directly without overspray. This can reduce paint shop time by approximately 50 minutes per two-tone vehicle. This process also advances customer sustainability goals by reducing CO2 emissions and eliminating energy-intensive air-filtering systems that handle overspray from the paint application process, reducing costs and improving efficiency.

“The process uses a direct printing approach rather than conventional spraying, eliminating overspray and masking,” Reil said. “It allows the application of coatings in an extremely precise manner, giving the ability to combine both sustainability and customization. In the future, complete cars might be painted using precision application technology, offering manufacturers even more options to enhance the appeal of their vehicle models.”

PPG: WE PROTECT AND BEAUTIFY THE WORLD™

At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for more than 135 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $13.8 billion in 2020. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.

We protect and beautify the world is a trademark and the PPG Logo is a registered trademark of PPG Industries Ohio, Inc.

CATEGORY Automotive OEM Coatings

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PPG Media Contacts:
Andrew Wood
Corporate Communications, EMEA
+31 6 5121 6579
awood@ppg.com

Keith Rigby
Automotive OEM Coatings
+1 412-434-1718
krigby@ppg.com
www.ppg.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye